Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Giovanni Luigi Di Maria Added: 2 years ago
TCT 23 - We are joined by Dr Giovanni Luigi Di Maria (John Radcliffe Hospital, UK) to discuss the findings of the PICSO-AMI-I study (NCT04958421), sponsored by Miracor Medical. The PICSO-AMI-I study aimed to assess the safety and feasibility of pressure-controlled intermittent coronary sinus occlusion (PiCSO) in patients with ST-elevation myocardial infarction (MI), presenting with TIMI 0 or 1… View more
Author(s): Nazli Okumus , Jeffrey L Carson Added: 2 years ago
AHA 2023 — Investigator, Dr Jeffrey Carson (Rutgers University, US) joined Dr Nazli Okumus, CardioNerds Ambassador to discuss findings from the MINT trial (NCT02981407).The aim of this randomised, parallel assignment trial (Rutgers) is to compare liberal and restrictive red blood cell transfusion strategies in patients who have had an acute myocardial infarction (AMI) and are anemic… View more
Added: 1 year ago
In this week's episode of Parallax, host Dr Ankur Kalra engages in a thought-provoking discussion with Dr Stephen Smith, a pioneer in electrocardiography and myocardial infarction diagnosis. They delve into the groundbreaking OMI/NOMI paradigm (Occlusion MI vs Non-Occlusion MI), challenging the traditional STEMI vs non-STEMI terminology that has long been the cornerstone of acute coronary… View more
Author(s): Joost Daemen Added: 1 week ago
American College of Cardiology Congress 2026 - Dr Joost Daemen (Thoraxcenter, Erasmus University Medical Center, Rotterdam, NL) joins us to discuss findings from the FAST III trial (NCT04931771; ECRI) a large-scale randomised study comparing fractional flow reserve (FFR) with 3D-quantitative coronary angiography-derived vessel FFR (vFFR) to guide coronary revascularisation.This randomised, open… View more
Added: 2 weeks ago Source:  Cardiac Failure Review
The optimal timing for complete revascularisation in patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel disease who also present with heart failure is a key clinical question. A pre-specified subgroup analysis of the OPTION-STEMI trial suggests that a staged approach may be preferable to immediate complete revascularisation in this high-risk patient group… View more
Added: 2 weeks ago Source:  Interventional Cardiology Review Journal
Long-term follow-up from the FAMOUS-NSTEMI trial suggests that a fractional flow reserve-guided strategy for managing patients with non-ST-segment elevation myocardial infarction (NSTEMI) does not reduce adverse cardiovascular outcomes compared to standard angiography-guided care.¹MethodologyFAMOUS-NSTEMI was a prospective, randomised, controlled trial that enrolled 350 patients with NSTEMI… View more
Added: 4 weeks ago Source:  ICR3 Journal Radcliffe Cardiology
The optimal timing for treating nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease remains a topic of clinical debate. The iMODERN trial sought to clarify this by comparing outcomes between an immediate, physiology-guided percutaneous coronary intervention (PCI) strategy and a deferred, imaging-guided approach.¹˒²MethodologyThe… View more
Author(s): Pasquale Santangeli , Dhanunjaya Lakkireddy Added: 1 month ago
Dr Dhanunjaya Lakkireddy (Kansas City Heart Rhythm Institute, Kansas City, US) and Dr Pasquale Santangeli (Cleveland Clinic, Cleveland, OH, US) discuss evidence-based strategies for preventing complications during complex atrial fibrillation and ventricular tachycardia ablation procedures.This expert discussion focuses on safety considerations in high-risk electrophysiology procedures, comparing… View more